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ABSTRACT
Endothelial nitric oxide synthase (eNOS) is part of a family of three nitric oxide
synthase (NOS) enzymes that catalyze the production of nitric oxide (NO). NO is a
gaseous, free-radical signaling molecule that has a variety of cellular and physiological
functions that range from maintaining cardiovascular homeostasis to neurotransmission.
The function of NO greatly depends on the concentration and is cell type specific. eNOS
is the most regulated of the three NOS isoforms and the mechanisms of regulation can be
through protein-protein interactions and posttranslational modifications. A connection with
eNOS and the cell cycle has begun to form with recent research identifying eNOS as a
substrate of cyclin-dependent kinases (CDK). CDKs are one of the regulatory elements in
cell cycle progression and form a class of serine/threonine kinases. The most commonly
studied and well understood posttranslational modification of eNOS is phosphorylation.
This work builds on our laboratory’s discovery of a phosphorylation site – ser600 – on the
autoinhibitory loop of eNOS. Our work finds a novel connection between phosphorylation
at this site and mitosis.
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CHAPTER 1 – INTRODUCTION
Nitric Oxide and its Physiological Relevance
Nitric oxide (NO) is a gaseous free-radical molecule that, while short-lived,
regulates a plethora of physiological functions that are both concentration and
location/context dependent (1-5). For example, in the nervous system, NO can act as a
neurotransmitter (4). In the cardiovascular system, NO can act as a vasodilator mediating
endothelium-based relaxation of blood vessels (1). Additionally, NO can influence
multiple cellular events ranging from apoptosis to cell cycle arrest (2-5). NO has even been
implicated in several cancer-related events that include angiogenesis, anti-apoptotic
mechanisms, tumor cell invasion, and metastasis (5). Overall, NO is a potent bioactive
molecule that influences an abundance of physiological functions.
Physiological dysregulation can arise when too much or too little NO is produced.
A high level of NO is associated with oxidant induced pathogenesis which can result in
tissue damage and hypertension in the cardiovascular system (6). On the other hand, a low
level of NO is associated with compromised immune function, increased development of
cardiovascular issues like hypercholesterolemia, and is linked to exacerbation of diabetic
symptoms (7).
NO is a free radical and as such, has high reactivity with just about all molecules.
Physiologically, NO is not the only free radical that is produced. Some of these radicals
can be formed from molecules reacting with NO. In fact, there is reasonable variety in the
physiologically relevant intracellular free radicals, shown in table 1 below (8). Each radical
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can react with a multitude of molecules ranging from proteins to other signal mediators
which can alter normal cellular function.
Table 1: Summary of Different Reactive Oxygen Species and Half-life (8)
Reactive Species Symbol
Half-life
Superoxide
O2
10-6 s
Hydroxyl
HO
10-10 s
Alkoxy
RO
10-6 s
Peroxyl
ROO
17 s
Hydrogen
H2O2
Stable
peroxide
1
Singlet oxygen
O2
10-6 s
Nitric oxide
NO~ 7 s*
Nitrite
NO2
110 s
Nitrate
NO3
5-8 h
Nitrous acid
HNO2
-3
Peroxynitrite
ONOO
10 s
Alkyl
ROONO
peroxynitrite
Dinitrogen
N2O3
trioxide
Dinitrogen
N2O4
tetroxide
*- Dependent on environment; for example, can last minutes in air saturated solutions

Nitric Oxide Synthases
One of the things that makes NO unique is the short biological half-life it has, which
means it must be actively produced when necessary by nitric oxide synthase (NOS)
enzymes. Nitric oxide synthases comprise the class of enzymes that is responsible for the
production of NO through the conversion of L-arginine to citrulline producing NO (9); this
reaction is shown below in figure 1. NOS enzymes have three main isoforms, neuronal
(nNOS; NOS1), inducible (iNOS; NOS2), and endothelial nitric oxide synthases (eNOS;
NOS3) (10). All three enzymes in the family use the same cofactors including heme,
tetrahydrobiopterin (BH4), flavin mononucleotide (FMN), flavin adenine dinucleotide
7

(FAD), zinc, and nicotinamide adenine diphosphate (NADPH). All three enzymes form
homodimers, which are required for activity (11). All three enzymes carry out the same
enzymatic reaction that consumes 2 moles of L-arginine, 3 moles of NADPH, 3 moles of
H+, and 4 moles of O2 to produce 2 moles of L-citrulline, 2 moles of NO, 4 moles of water,
and 3 moles of NADP+ (figure 1). While all three enzymes can catalyze the same reaction,
the amount of NO produced varies from isoform to isoform with iNOS producing the most,
nNOS producing short bursts, and eNOS producing long pulses. The three isoforms also
have the same general structure, a bidomain protein consisting of a C terminal reductase
domain and an N terminal oxygenase domain with a calmodulin binding site linking the
two domains together. Calmodulin binding is necessary to produce NO. One region that is
not conserved between all three of the enzymes is a stretch of 52-55 amino acids that forms
an autoinhibitory region between the two domains. This region is present in nNOS and
eNOS but not iNOS (12). Another difference that exists between the three enzymes is tissue
expression. Neuronal NOS is expressed constitutively in peripheral and central neurons
(10). Inducible NOS is not constitutively expressed in cells but can be induced to express
in nearly all cells as a response to various stimuli, like inflammation (10). Endothelial NOS
is constitutively expressed most commonly in endothelial cells but can be found in cells

Figure 1: Nitric Oxide Synthase enzymatic reaction showing conversion from L-arginine to Lcitrulline producing NO. This reaction consumes 2 moles of L-arginine, 3 moles of NADPH, 3 moles
of H+, and 4 moles of O2 to produce 2 moles of L-citrulline, 2 moles of NO, 4 moles of water, and 3
moles of NADP+.
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like the trophoblasts of the human placenta and kidney tubular epithelial cells (10,13). The
focus of this study will be on eNOS in endothelial cells.

Endothelial Nitric Oxide Synthase
eNOS is primarily expressed in cardiovascular tissue, specifically endothelial cells
(14). The endothelium comprises the inner lining of all blood vessels and is generally
divided into two major categories, microvasculature (capillaries) and macrovasculature
(arterial and venous). For example, the aorta contains macrovascular endothelial cells
whereas dermal capillaries contain microvascular endothelial cells. The endothelium
maintains a large amount of eNOS compared to other tissues, this is because NO is potent
vasodilator and helps to maintain cardiovascular homeostasis (10). eNOS is also unique
among the NOS enzymes due to the degree of posttranslational modifications involved in
regulation. Specifically, unlike other NOSs, eNOS is palmitoylated and myristoylated on
the n-terminus which allows for localization on the plasma membrane (3). Of these two
modifications, palmitoylation is reversible whereas myristoylation is not. In addition to the
plasma membrane, eNOS is also found associated with the Golgi apparatus and in the
cytoplasm of endothelial cells (15). It has been established that eNOS is found in multiple
subcellular pools – plasma membrane, cytoplasm, and the Golgi apparatus (16). However,
the full mechanism of how eNOS achieves differential subcellular localization is not
clearly understood. The consensus in the literature suggests that eNOS must be on the
plasma membrane in order to achieve maximal enzymatic activity. Membrane localization
of eNOS allows for diffusion of NO across the membrane onto the underlying smooth
muscle tissue which results in the signal for vasodilation. The Golgi pool of eNOS is less
active compared to membrane associated eNOS, likely due to limited access to substrates.
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Regulation of Endothelial Nitric Oxide Synthase through Phosphorylation
The most commonly studied form of eNOS regulation is through phosphorylation
which has resulted in the identification of multiple phosphorylation sites. Each site
influences eNOS differently resulting in functional enhancement, inhibition, or a change
in cellular interactions. Most of the identified phosphorylation sites on eNOS are serines
or threonines. Of them, the first identified and most commonly studied site is ser1177;
modification at this residue enhances NO production by enhancing electron flow in the
reductase domain which increases the activity of eNOS (17, 18). Additional known
activation sites include ser615 and ser633 (19, 20). The most well studied inhibitory site is at
thr495; phosphorylation at this residue blocks calmodulin association and therefore ablates
NO output (21). Other phosphorylation sites are present on eNOS but have some ambiguity
with regards to altering NO output. One site, ser114, has been shown to be inhibitory in vivo
not in vitro, with the current consensus suggesting that phosphorylation at this residue
increases association of eNOS to negative cofactors resulting in reduced in vivo activity
(22, 23). Our lab has recently identified a new phosphorylation site, ser600 (24). Ser600 is
found in the eNOS autoinhibitory loop near two activating sites, ser615 and ser633.
Additionally, two tyrosine phosphorylation sites have also been identified on eNOS, tyr81
and tyr657 (25-27). Phosphorylation at tyr81 has been shown to be activating while tyr657 is
thought to be inhibitory (26). Despite the numerous phosphorylation sites, little
investigation has been done on their regulation during the cell cycle which opens another
potential avenue understanding for eNOS function and regulation. Known phosphorylation
sites are summarized in Table 2.
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Table 2: Summary of the phosphorylation sites of eNOS and the resulting
difference in NO output by residue type
Residue Type: Residue
Activating/Inhibiting Reference
Number:
Serine
114
Inhibiting (in vivo)
22-23
600
Inhibiting (in vitro)
24
615
Activating
19
633
Activating
20
1177
Activating
17-18
Threonine
495
Inhibiting
21
Tyrosine
81
Activating
26
657
Inhibiting
26

Endothelial Nitric Oxide Synthase and the Cell Cycle
Recently, evidence suggests that eNOS may play a role in cellular proliferation by
interacting with a variety of genes (28). One study identified that eNOS deficiency in mice
resulted in reduction of collateral vessel density due to impaired activation of a cell cycle
gene network during arteriogenesis. Additionally, the same group found that eNOS
maintains a role in collateral remodeling by regulating cell proliferation (28). Collateral
blood vessels are abnormal blood vessels which connect the aorta to pulmonary arteries.
Arteriogenesis is like angiogenesis but refers to increasing the size in the diameter of
existing arteries rather than the formation of new vessels entirely. Furthermore, the same
study found that, eNOS knockout mice were not able to upregulate between 40-44 genes
related to the cell cycle and could result in altered cell cycle progression (28). In other
studies, transfer of the NOS 3 gene into vascular smooth muscle and human embryonic
kidney cells was shown to inhibit cellular proliferation in both types of cells (12, 29).
Ultimately, there is limited data available in the literature that directly measures the impact
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of eNOS on cell cycle progression, further research is necessary to establish the nature of
the linkage.
There is considerable evidence that suggests eNOS may be actively regulated as the
cell cycle progresses as part of global cellular mechanisms of regulation like
phosphorylation. Two separate research groups have shown that eNOS is phosphorylated
by CDK 1 and CDK 5 at ser114 (30-31). Phosphorylation of ser114 caused lowered nitrite
production in SH-SY5Y cells transfected with both eNOS and CDK5/p35 (30).
Additionally, CDKs 1, 2, and 5 were shown to phosphorylate ser114 in vitro and treatment
with roscovitine, a CDK 1, 2, and 5 inhibitor prevented phosphorylation in vivo (31) This
opens the possibility that eNOS may be regulated through CDKs. Another study has shown
that VEGF mediated ser1177 phosphorylation is linked to vein formation in embryonic
endothelial cells and regulates the formation of blood vessels (32). Besides
phosphorylation, eNOS is regulated through interactions with other proteins like
calmodulin. Another protein that interacts directly with eNOS is NOS interacting protein
(NOSIP). NOSIP has been shown to interact with eNOS in a cell cycle dependent
mechanism and is a nuclear ubiquitin ligase that is released to the cytoplasm as part of late
cell cycle (33). Specifically, eNOS was shown to be downregulated during G2 phase
through NOSIP-mediated subcellular localization of eNOS to the cellular cytoskeleton.
Additionally, the activity of eNOS is lower in G2 compared to G1, this is reversed when
NOSIP is knocked down by siRNA (33) Taken together this data opens the possibility that
eNOS may be actively regulated during the cell cycle, specifically through an
ubiquitination event that is cell cycle dependent. In this study, we present data that supports
a connection between the cell cycle and eNOS. We have found that eNOS is increasingly
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phosphorylated at ser600 during mitosis in human microvascular endothelial cells using
immunofluorescence, flow cytometry, and western blot analysis.
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CHAPTER 2 – EXPERIMENTAL
Structure-based Sequence Alignment
Materials
eNOS sequences were collected from the Swiss UniProt database manually.
Sequences were aligned using the MUSCLE algorithm in Jalview 2.10.5. Jalview and
Microsoft Word were used to analyze aligned eNOS sequences. A threaded model of the
unstructured region of eNOS was made using Swiss-Model. The model was analyzed and
refined in PyMol 2.3.2.
Methods
eNOS protein sequences were collected using the “Add to basket” feature on the
Swiss UniProt website following a blast query using the protein sequence of human eNOS.
Sequences were only selected if more than 70% sequence homology was observed.
Sequences were then compared to nNOS and iNOS and excluded if the PDZ domain and
autoinhibitory loop matched nNOS or if no autoinhibitory loop was present. This resulted
in a collection of 84 eNOS protein sequences from a variety of chordate species, primarily
mammalian but also including some reptiles. It is worth noting that if this study is repeated,
additional nonmammalian sequences should be collected. The collected sequences were
downloaded in FASTA format and imported into Jalview and aligned using the MUSCLE
alignment preset. The rendered sequence alignment was then truncated from the full length
eNOS to only include the alignment region that matches with amino acid residues 566-674
of human eNOS which includes the autoinhibitory loop. This region was then blasted on
the Swiss UniProt website to determine a protein of high homology and resolved structure.
14

Based on this query, the human iNOS reductase and calmodulin complex flavodoxin-like
domain was found (PDB 3HR4 (35)). The human eNOS flavodoxin-like domain from
amino acid residue 520 to 703 was then queried into the Swiss-Model using 3HR4 as a
template to create a threaded model of the autoinhibitory loop (AIL) of eNOS. The model
of the AIL was then opened in PyMol and aligned to the flavodoxin-like domain of iNOS
from 3HR4. Regions of structural homology in the model that correspond to the structure
from 3HR4 were rendered in color and regions of unknown structure, mainly encompassing
the autoinhibitory loop, were left gray. Using the sequence alignment, outliers were
removed that maintained low homology in the AIL, and regions of structural homology
were color coded to match the model in Microsoft Word.

Cell Culture
Materials
HMEC-1 cells (CRL-3243) were purchased from the American type culture
collection (ATCC). MCDB 131 and hydrocortisone were purchased from Sigma-Aldrich.
Epidermal growth factor (EGF), L-glutamine, and trypsin were purchased from Genesee
scientific. Fetal bovine serum (FBS; E17063) was purchased from Atlanta Biologicals.
Methods
Human microvascular endothelial cells (HMEC-1) were cultured as directed by the
ATCC in MCDB 131 media with 10% FBS, 10 ng/mL epidermal growth factor, 1 μg/mL
hydrocortisone, and 10 mM glutamine. Fully supplemented media is referred to as
complete media. The cells were grown at 37 degrees C in a humidified environment with
5% CO2 and passaged once 80-90% confluency was reached. Experiments used cells
between passages 4-13 and were seeded into vessels dependent upon the experiment being
15

done – see the subsections for each method to determine what vessel was used and how it
was seeded.
For maintenance passages in a T75 flask, media was aspirated, and cells were
washed once for 45-60 seconds with 2 mL of trypsin which was then aspirated out of the
flask. The cells were then trypsinized off the surface with 3 mL of trypsin incubated for 5
minutes at 37 degrees C. It is worth noting that HMEC cells tightly adhere to surfaces so
additional time may be required to remove all the cells from the surface. The trypsin was
quenched with 1:1 ratio of complete media to trypsin. Then a portion of the quenched
solution of trypsin and cells was moved into a T75 flask, at a dilution appropriate for the
density of cells in the flask and the density desired. For example, consider a 1:3 dilution, 2
mL of the cells in a trypsin/media mixture were added to 10 mL of complete media which
was then placed into a T75 flask for a total volume of 12 mL. For experiment use, all of
the steps are repeated, however instead of moving the quenched solution into a flask, a
sample was collected, and the cells were counted before diluting the cells to the desired
number and volume prior to placement into the experiment specific vessel.

G2/M cell cycle synchronization
Materials
RO-3306 was purchased as a 10 mM stock in DMSO from MedChemExpress.
Methods
Cells were synchronized at the G2/M barrier using a CDK 1 inhibitor, RO-3306.
The inhibitor was added to a final concentration of 5 μM to adherent cells in experiment
specific vessels from a 10 mM stock solution prepared in DMSO (Med Chem Express).
16

The inhibitor treatment lasted 20 hours, then cells were washed once with unsupplemented
MCDB 131 then complete media was added to initiate the time course. The amount of
media added was dependent on the experimental method being used. The washout of the
RO-3306 releases the cells from the G2/M barrier resulting in elevated populations of
mitotic cells. It is worth noting that before use of this inhibitor, serum starvation was
attempted to synchronize cells, however, the HMECs are hardier than anticipated and a 20
hour serum starvation was not enough to arrest cells in G0. Therefore, if serum starvation
is used in the future, a minimum of 24 hours, preferably 48 hours should be utilized.

Immunofluorescence
Materials
Lab-Tek 16-well Chamber Slide and coverslips (178599 and 171080) were
purchased from ThermoScientific. PBS supplemented with calcium and magnesium (25508CB) was purchased from Genesee Scientific. 20% PFA (15713) was purchased from
Electron Microscopy Sciences. Horse serum was purchased from Atlanta Biologicals. See
appendix for primary and secondary antibodies and dilutions of antibodies used.
Methods
HMEC-1 cells were collected as previously described and seeded into 16-well
chamber slides at a density of 0.5 x 104 in 100 μL of media. After experimental treatment,
cells were fixed with 4% PFA in PBS for 15 minutes at room temperature. Cells were then
washed with 100 μL of PBS per well three times, then simultaneously blocked and
permeabilized with 5% horse serum and 0.3% Triton x-100 respectively in PBS. All
primary antibody staining was done overnight at 4°C with antibody specific dilutions –
listed in the appendix – prepared in blocking buffer (5% horse serum, 0.3% Triton X-100,
17

and 0.01% sodium azide in PBS). After primary staining, cells were washed three times
with 100 μL of blocking buffer per well. Then secondary antibody staining was done at
room temperature for 45 minutes with manufacture recommended dilutions – also listed in
the appendix – prepared in blocking buffer. Cells were washed two times with blocking
buffer. Then nuclei were stained with DAPI in PBS, then cells were rinsed with PBS. The
wells on the chamber slide system were then removed with brute force and the underlying
silicon gasket was carefully lifted using fine tipped forceps. Once the gasket was removed,
the slide was rinsed in PBS once, then mounted with Vectashield H-1000. Slides were
imaged on a Zeiss LSM 700 confocal microscope. Images were processed and analyzed
using Zeiss Zen Black and Blue software.

Flow Cytometry
Materials
Sterile 5-mL polypropylene tubes (21-125) were purchased from Genesee
Scientific. RNase A (120-91-021) was purchased from Invitrogen. Bovine serum albumin
(BSA) was purchased from Fisher Scientific.
Methods
HMEC-1 cells were seeded into experiment specific containers with experiment
specific seeding densities. Depending on the experiment, the cells were or were not treated
with RO-3306. Following the treatment or lack of treatment, cells were trypsinized
following the same protocol as for passaging cells with the alteration of including 3% BSA
in PBS for quenching the trypsin instead of complete media. The cells were then spun down
at 200xG for 5 minutes, then the quenching solution was aspirated and 1% PFA in PBS
was added to fix the cells in suspension. The cells were fixed for 15 minutes at room
18

temperature, then the cells were washed with 2 mL of PBS, spun down at 200xG for 5
minutes, and then supernatant was collected into PFA waste. The cells were then blocked,
permeabilized, and RNase treated for 30 minutes with 3% BSA, 0.1% Triton X-100, and
100 μg/mL of RNase A in PBS. The cells were then filtered through a 30 μm mesh and
counted, cells were then resuspended to 10E6 cells/mL in 3% BSA in PBS. Then, 300 μL
of cells were aliquoted into 5-mL sterile cell culture tubes – ensuring that an unstained and
single stain samples were also collected – see the table below for an example of how cells
were divided for an experiment. The ser600 phosphospecific antibody primary was diluted
in 3% BSA in PBS and added to the cells to a final dilution of 1:200 for primary staining.
The eNOS-Alexa Fluor 647 conjugated primary was used as the manufacturer specified,
20 μL / 100,000 cells. The primary was incubated for 30 minutes at room temperature. The
cells were then washed by centrifugation with 4 mL of ice cold 0.5% BSA in PBS at 200xG
for 5 minutes. The secondary staining was also done following manufacturer recommended
dilutions with the same conditions as the primary staining. Propidium iodide was added to
50 μg/mL final concentration to the secondary staining solution to simultaneously stain
DNA and detect the primary antibody with a labeled secondary antibody. Finally, excess
antibody and PI was washed out by centrifugation with the same conditions as for washing
out the primary. The cells were resuspended in approximately 250 μL of PBS and samples
were then run through a BD Accuri C6 flow cytometer with a fast flow rate with an
unlimited volume until almost the entire sample was read. Data was analyzed using FlowJo
10.
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Western Blotting
Materials
Gel electrophoresis and western transfer reagents were made in house. Mini protean
TGX 8-16% gradient gels (Ref #: 456-1103), gel electrophoresis equipment, and western
transfer equipment were purchased from Bio-Rad. Prometheus OneBlock Western-FL
Blocking Buffer was purchased from Gennesee Scientific. TBST was made in house.
Protease inhibitor cocktail and Pierce 660 nm protein assay reagent were purchased from
ThermoScientific. See appendix for primary antibodies and dilutions of antibodies used.
Methods
Approximately 7 x 105 HMEC-1 cells were seeded into 8 10 cm2 dishes and allowed
to grow for 1.5 days before treatment with RO-3306 or DMSO for 20 hours. After
treatment, the RO-3306 inhibitor was washed out of the 8 dishes of cells, each with slightly
differing conditions – vehicle (DMSO), 0 mins, 15 mins, 30 mins, 45 mins, 60 mins, 90
mins, and 120 mins after washout. This allows for a time course with time points that
captures cells as they initiate and progress through mitosis. Cells were harvested by lifting
with a cell lifter into ice cold lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.4 at 4C),
1.5 mM MgCl2, 10% glycerol, 1% Igepal, and 0.5% Triton X-100) supplemented with 1X
protease inhibitor cocktail, 1 μM micro-cysteine, and 2 μM sodium vanadate. Lysates were
flash frozen with a splash of liquid nitrogen and placed into the -80C for storage until
sample preparation. For sample preparation, lysates were spun down at 18,000xG, the
supernatant was collected, and the pellet was discarded. A Pierce 660 nm protein assay was
done using samples of the supernatants as specified by the manufacture for a microplate
assay. Once the protein concentration was determined, samples were prepared by adding
20

4X sample buffer with 100 mM DTT to a final concentration of 1X and 25 mM DTT.
Samples were then boiled for 5 minutes while a calculation was performed to determine
the volume of each sample necessary to load 15 μg of protein onto a 10% SDS gel. Gels
were run at 30 mA until the dye front had run off the gel. Proteins were then transferred
onto PVDF membrane using the tank method for western transfers. The condition for
transfers was 100 V constant for 60 minutes at 4C. Blots were blocked for 1 hour in
OneBlock. Primary antibodies were diluted in OneBlock to manufacturer recommended
specifications – see appendix for specific dilutions used – and incubated overnight at 4C.
Blots were washed 5 times total – 1 fill and dump, 3 5-minute washes, and 1 fill and dump
in that order – with TBST. Secondary was diluted in OneBlock to a final dilution of
1:15000 and blots were incubated for 45 minutes at room temperature. The blot was washed
the same as after primary antibody staining and scanned on a Licor Odyssey and data was
analyzed using ImageStudio 5.2.
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CHAPTER 3 – RESULTS
The autoinhibitory loop is highly conserved
Comparison of primary eNOS sequences from 50 different species shows that the
autoinhibitory loop (AIL) is highly conserved across the species studied (figure 3). The
sequence alignment is highlighted based on homology to Homo sapien eNOS. The
mammalian sequences are conserved throughout the entire AIL (shown in grey in figure 2)
with the most significant variation existing at the val616, which is conservatively substituted
for an isoleucine in some mammals including humans. This conservative mutation likely
stems from a base substitution event at the first base in the codons ATT, ATC, or ATA for
valine to GTX for isoleucine where X is any base. When comparing eNOS orthologs from
closely related taxonomic orders, we observe some minor divergences. Specifically, serine
residues substituted for threonine residues and lysine residues for arginine residues occur,
but these alterations are unlikely to change the overall structure or activity of the protein.
Only one organism is shown per genus, also some exceptions were encountered like Ursus
americanus where insertion or deletion events have significantly altered the AIL, but these
were removed from the final sequence alignment.
Phosphorylation sites on eNOS are conserved
Many of the phosphorylation sites that influence activity changes in eNOS are
highly conserved throughout mammalian eNOS orthologs. These sites include tyr81, thr495,
ser615, ser633, tyr657, and ser1177, where the substrate specificity is maintained upstream and
downstream of the phosphorylation site. Ser114 is conserved in mammals but some variation
occurs in the substrate specificity sequence. In primates, the amino acid after ser114 is
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Figure 2. Alignment of human nNOS, human iNOS, and chordate eNOS sequences highlighting
structural similarities. Colored residues represent conserved structural elements and are highlighted
when identical to human eNOS. Highlighted colors correspond to secondary structural elements found in
the structural model of the eNOS flavodoxin-like domain shown in figure 4. Arrows indicate beta strands
and cylinders indicate alpha helixes. Conserved phosphorylation sites are indicated by an asterisk. Ser 600
is highlighted in purple and indicated with a “?” on the sequence. The autoinhibitory loop is highlighted
in grey.

pro115, but this proline is replaced with a glutamine in other closely related mammalian
orders which would likely change the kinase capable of phosphorylating this site to a kinase
that is not proline directed. Ser615, ser633, and tyr657 are indicated by an asterisk on figure 2.
Phosphorylation sites significantly distant (tyr81, ser114, thr495, and ser1177) from the AIL are
not shown in figure 2. Ser600 is highly conserved in mammals and marsupials, but not
conserved in eNOS orthologs from more divergent taxonomic orders like birds,
amphibians, and reptiles (shown without ser600 in the lower portion of figure 2). This
suggests that ser600 may have some evolutionary significance in mammalian eNOS
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orthologs. This observation is supported by the phylogenetic tree of NOS enzymes
published by Andreakis et al (34). Specifically, at the branch point between avian eNOS
orthologs and the most common ancestral eNOS ortholog between mammals and
marsupials. However, as this information comes from a limited dataset, the study should
ultimately be independently repeated with additional data.
Structural elements of the autoinhibitory loop are conserved.
Structurally, the AIL has not been elucidated, likely due to flexibility in that region.
In all the crystal structures available for NOS enzymes, this region did not provide electron
density and may be a flexible region of the protein with inconsistent positioning in the
crystals. The region is highly conserved across mammalia and reptilia. Due to the lack of
structural data of the AIL, a threaded model of that loop and the surrounding domain was
made using the crystal structure of the flavodoxin-like domain of iNOS found in PDB
3HR4 shown in figure 3. From this model and a comparison of the sequences (figure 2),
multiple beta sheets and alpha helixes were found to be conserved (highlighted in cyan,
green, yellow, and red in figure 1 to match the colored regions of the model in figure 3).
The AIL had virtually no structurally resolved information, the closest comes from rat
nNOS reductase domain (PDB 1TLL (36)), but only a few amino acids within the rat nNOS
AIL had structural information associated with them resulting in a small resolved helix.
However, this helix may not be present in eNOS due to differences in the primary structure
around that region. Comparing the primary structure within the AIL between nNOS and
eNOS, it appears that eNOS has more hydrophobic residues (leu622, val623, and trp626)
which could be contributing to a small hydrophobic pocket that is absent in the nNOS. The
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Figure 3. Structural model of the flavodoxin-like domain of eNOS. The model was created using
Swiss-model with the structure of human iNOS bound to calmodulin used as the template (PDB 3HR4).
The colored regions represent areas of high structural homology, whereas the grey region is of unknown
structure and encapsulates the autoinhibitory loop of eNOS. Ser 600 is shown in purple. Ser615 and ser633
are shown in pink. The proposed MAPK binding domain is shown in yellow in the AIL. Tyr 657 is shown
in orange. FMN is shown in pale yellow.

amino acid residues at these positions in nNOS are small, polar amino acids (ser822, gln823,
and ser825). One explanation is that eNOS maintains a small hydrophobic pocket which is
absent in at least the reported structure of 1TLL of nNOS. Another explanation could be
differences in binding partners for nNOS and eNOS, where the eNOS AIL uses
hydrophobic interactions with its binding partners and whereas the nNOS AIL uses charged
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interactions with its binding partners. Overall, conclusions are difficult to make about the
structural nature of the AIL due to the lack of structural data in that region. However, the
distance of ser600 from the FMN in the structure, makes it is unlikely that phosphorylation
perturbs the electron transport occurring near the FMN and therefore as our most current
data suggests (supplemental figure 1), ser600 phosphorylation may not influence nitric oxide
production directly. However, phosphorylation here could influence eNOS binding
partners due to the hydrophobic amino acid residues located near ser600 in the model. With
regards to the eNOS dimer, ser600 is positioned within the FMN binding region of the eNOS
monomer. This is not associated with the dimerization interface in either the oxygenase or
reductase domain of the eNOS monomer (37).
Ser600 phosphorylation is modulated in a small subpopulation of late cell cycle HMEC cells
The physiological significance of phosphorylation of eNOS at ser600 has not been
characterized. Only one reference exists on this site from our lab. To better understand the
importance of this highly conserved site in mammals, we used immunofluorescence to
observe P-ser600 with a phosphospecific antibody in cycling endothelial cells (figure 4). We
found that only a small subpopulation of cells showed significant staining with this
antibody. A pattern of the staining was that only cells partially released from the growth
surface and cells that were rounded up showed increased staining (figure 4A). This led us
to believe that either apoptotic or mitotic cells were showing P-ser600. Based on the DNA
morphology, it initially appeared that cells that have heightened phosphorylation at ser600
have condensed DNA and are mitotic as two cells are in metaphase and one cell is in
anaphase (figure 4A). To follow up on this, flow cytometry was deployed to assess DNA
density and to characterize the cell cycle of P-ser600 elevated cells (figure 4B). We observed
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that P-ser600 was found in cells that primarily have N=4 DNA. This indicated that cells
positive for ser600 phosphorylation were at G2/M phase. Comparatively, cells that show
basal staining for P-ser600 have cells at N=2, 2<N<4, and N=4 DNA indicating that G1, S,
and G2/M phase cells are observed (figure 4B). Additionally, no DNA fragmentation was
observed in P-ser600 elevated or basal cells leading us to surmise that apoptotic mechanisms
are not correlated with the phosphorylation of ser600. Taken together with the DNA staining
in immunofluorescence, we believe that ser600 phosphorylation is modulated during mitosis
in microvasculature, making our lab the first to link this phosphorylation site to other
regulatory processes in the endothelium.

Figure 4. eNOS ser600 phosphorylation is only observed in a subpopulation of cells. Representative
image of indirect immunofluorescence (A) and indirect flow cytometry (B) demonstrating that ser600
phosphorylation is observed at high levels a small subpopulation of cells. Observations are representative
of four independent experiments. Scale bar represents 20 μm.
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Figure 5. eNOS ser600 phosphorylation is elevated with mitosis. Representative data of indirect flow
cytometry demonstrating that treatment with 5 μM RO-3306 results in reversible G2/M synchronization
(A) and that Ser600 is elevated by treatment with RO-3306 and washout of inhibitor (B). Representative
image of indirect immunofluorescence showing that with washout of 5 μM RO-3306, a G2/M inhibitor,
the population of mitotic cells increases as well as ser600 phosphorylation, scale bar represents 50 μm (C);
a magnified image of two cells in metaphase is shown, scale bar represents 20 μm (D). Observations are
representative of three independent experiments.
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Ser600 phosphorylation is elevated in mitotic endothelial cells
Given that ser600 phosphorylation was observed in cells that appear to be in late cell
cycle or in G2/M phase based on the DNA content, we further investigated the point of
modulation for P-ser600 in the cell cycle. To investigate this, we deployed a reversible CDK
1 inhibitor that arrests at the G2/M barrier – RO-3306. Upon washout of the inhibitor, cells
rapidly begin mitosis (figure 5A). We observed an increase in P-ser600 after RO-3306
treatment (figure 5B). Using immunofluorescence and staining with anti-histone H3 ser28
phosphorylation – a mitotic indicator – we observed strong concomitant staining between
the two antibodies (figure 5C). Magnification of the staining is shown in figure 5D. This is
reflective of P-ser600 being modulated during the cell cycle and confirms that P-ser600 is
modulated in specific circumstances during the start of mitosis and not during G2 phase.
Additionally, flow cytometry following 45 minutes after the RO-3306 washout showed
roughly 6 times greater proportion of cells P-ser600 elevated compared to the vehicle
control. Suggesting P-ser600 is modulated by a kinase that is activated during early mitosis.
eNOS levels do not significantly change throughout the cell cycle
To ensure that the elevation in P-ser600 is not from changing levels of eNOS protein,
we employed additional immunofluorescence and flow cytometry. Using an anti-eNOS
monoclonal antibody in immunofluorescence, we found that eNOS staining is consistently
observed in cycling cells (figure 6A). To analyze a larger number of cells and to assess the
cell cycle, flow cytometry was used to observe eNOS while co-staining with propidium
iodide to measure DNA content. This showed us that eNOS positive cells were found at all
points of the cell cycle (figure 6B). When comparing DNA content to eNOS staining, little
difference is observed throughout the cell cycle, with eNOS levels staying at a relatively
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consistent level (figure 6C). Taken together, we believe that eNOS levels are remaining
consistent throughout the cell cycle and the P-ser600 is not elevated due to an increase in
eNOS protein.

Figure 6. Total eNOS is observed throughout the entire cell cycle. Representative image of indirect
immunofluorescence (A) and direct flow cytometry (B) demonstrating that eNOS is observed
throughout the cell cycle. eNOS protein levels are also relatively consistent throughout the cell cycle
when compared to PI staining (C). Observations are representative of three independent experiments.
Scale bar represents 20 μm.

Proximity ligation assay verifies P-ser600 antibody specificity
To build on our previous publication (24) and further validate our P-ser600 antibody
specificity to eNOS, we used an in-situ proximity ligation assay (PLA) kit from Millipore.
This kit was adapted from a publication by Söderberg et al. (38). Simplified, this assay uses
the principles immunofluorescence and rolling circle PCR. The immunofluorescence
component of the assay used the same steps as normal immunofluorescence, but replaced
fluorophore conjugated secondary antibodies with pseudo-secondary antibodies
conjugated to DNA oligonucleotides to detect bound primary antibodies – in this case, the
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BD Biosciences eNOS monoclonal antibody and our P-ser600 antibody. The rolling circle
PCR component used three things, additional DNA oligonucleotides to form a complete
circular sequence of DNA, a ligase to ligate this circular DNA, and a polymerase to amplify
the linear DNA conjugated to the antibody. Detection was accomplished using
complimentary DNA oligonucleotides conjugated to fluorophores. Signals using this PLA
kit are only produced when primary antibodies are within 40 nm of each other. In our study,
we observed little to no signal when no primary antibodies were used (figure 7A).
However, when using PLA with an eNOS monoclonal antibody and our polyclonal P-ser600
antibody, we observed punctate signals in the periphery of the cell (figure 7B). The
punctate signals are in similar position in the cell as observed when staining with the P-

Figure 7. Proximity ligation assay of an eNOS monoclonal antibody and the P-ser600 antibody.
Proximity ligation assay results using a mouse monoclonal eNOS antibody and our rabbit polyclonal
eNOS ser-600 phosphorylation antibody, without primary antibodies no signal is observed (A) whereas
when both antibodies are present signal is observed in mitotic cells (B). Scale bars represent 20 μm.
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ser600 antibody alone – on the periphery of the cell. This data supports the specificity of our
antibody and helps validate our previous observations with this antibody.
eNOS phosphorylated at ser600 is shifted by 10 kD on SDS-PAGE
Given that we can elevate the amount of P-ser600 observed by synchronizing cells
at the G2/M barrier, we wanted to collect semi-quantitative data using western blot
analysis. We confirmed our finding that eNOS phosphorylated at ser600 is elevated around
30-60 minutes after entrance into mitosis, and observed, under our western conditions, that
the P-ser600 antibody reacts with a band that is shifted by 10 kD when compared to eNOS
reactivity using several eNOS antibodies. We observe reactivity of the mouse monoclonal
eNOS antibody at approximately 140 kD whereas the P-ser600 antibody is reacting roughly
10 kD higher at approximately 150 kD (figure 8). It is worth noting that the eNOS antibody
does not also react with the 150 kD band unless we significantly increase the input. This
suggests that an amount of eNOS that can react with eNOS antibody is not present in the
heavier band and likely means that a smaller amount of eNOS is present at the heavier
band. Interestingly, reaction to a P-ser1177 antibody, which has an epitope that could overlap

Figure 8. eNOS P-ser600 is shifted by 10 kD on western blots. Western blot analysis shows that eNOS
P-ser600 is shifted by roughly 10 kD heavier than eNOS. Comparatively, eNOS modified by other
phosphorylation, including P-ser1177 is not shifted and has reactivity that overlaps with the eNOS
antibody.
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with the eNOS antibody used in this blot. Together, this suggests that P-ser600 may be coposttranslationally modified with a modification of roughly 10 kD.
Other eNOS phosphorylation sites are not changing significantly after RO-3306 washout
Using the same methodology to assess P-ser600 with western blotting, we
investigated other commonly studied phosphorylation sites on eNOS. We found that
phosphorylation at ser1177 is slightly elevated in cells at 15-120 minutes after RO-3306
washout when compared to the vehicle control and 0-minute (G2/M block intact) time
point. However, when compared to the degree of modulation of P-ser600, the change in Pser1177 and P- ser635 is minimally elevated compared to the vehicle treated cells.
Additionally, other sites like, ser114 and thr495 do not seem to be changing throughout the
time course (figure 9). It is worth noting that we did not explore phosphorylation of tyr
residues with our western blots which may be worth a brief investigation.

Figure 9. Western blot analysis of phosphorylation of other eNOS sites. Representative western blot
of two independent experiments showing phosphorylation status of multiple eNOS phosphorylation sites
following RO-3306 washout.
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MAPK activation does not correspond to the increase in eNOS P-ser600
Previous data from our lab showed that eNOS can be phosphorylated by MAPKs.
Specifically, eNOS is phosphorylated by ERK, JNK, and p38. Where JNK phosphorylates
at ser114, ERK phosphorylates at ser600, and p38 phosphorylates both sites (supplemental
figure 2). It is worth noting that MAPK phosphorylation was used as a measure of kinase
activity and that ideally, a substrate should be looked at to ensure activity. All three MAPKs
seem to be phosphorylated significantly at 15 minutes into the washout when compared to
the vehicle or 0-minute time point (figure 10). At first glance, this seems to match up with
the increase in eNOS P-ser600, but this does not appear to be entirely the case. P38
phosphorylation decreases by 30 minutes into the time course which makes it unlikely to
be the cause of peak P-ser600 at around 45 minutes (figure 10). JNK is unable to
phosphorylate eNOS at ser600 in vitro (supplemental figure 2). ERK maintains the
activation phosphorylation sites for the entire time frame which makes ERK more likely to
enhance P-ser600, however, the ERK phosphorylation lasts significantly longer than ser600
phosphorylation (figure 10).
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Figure 10. Western blot analysis of MAPKs. Representative western blot of two independent
experiments showing changes in MAPK phosphorylation following RO-3306 washout.
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CHAPTER 4 – DISCUSSION
In order to assess the possible significance of eNOS ser600 phosphorylation, we
created a multiple sequence alignment to verify that more than just humans and cows have
this phosphorylation site. The eNOS protein sequence alignment shows us that there is high
conservation throughout most of the primary and secondary protein structure of eNOS
(figure 1). We also found that all phosphorylation sites that influence activity are conserved
across taxonomical classes in our data set. Our data matches observations in a detailed
study on the phylogeny of NOS enzymes by Andreakis et al. However, it is still worth
mentioning that our data set is limited to a blast search using the protein sequence of eNOS.
Our study found that ser600 occurs exclusively in mammals and marsupials in our
data set. This suggests that as part of the evolutionary differentiation from reptiles and aves,
this site appeared in mammals. One possible explanation for the appearance of this site
may correspond with the branch that distinguishes cold-blooded animals from warmblooded animals. Our data suggests that ser600 may have been a more recent mutation in
eNOS which aligns with the phylogenetic analysis of NOS enzymes by Andreakis et al
(34). That study identifies eNOS as the last NOS enzyme to appear in organisms. However,
as there is limited data in the literature on this site in other species outside of cows, further
work is necessary before significant conclusions can be made on the evolutionary
significance of ser600.
Using the same sequence alignment, we found that all phosphorylation sites that
alter NO production by eNOS were conserved in our data set. However, ser114 and ser600
were only found in sequences from warm blooded animals in our study. We believe that
these sites do not directly influence NO production of eNOS by perturbing electron
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transport, but rather, influence eNOS binding partners which may contribute to the
ambiguity in activity differences observed in the literature (39). Another observation stems
from a conserved phosphorylation site between tyr657 on eNOS and tyr895 on nNOS.
Phosphorylation at this site has inverse effects between the two NOS enzymes where on
eNOS it inhibits activity, but on nNOS it enhances activity. This likely results from other
differences found on the nearby AIL. In nNOS, the region has fewer hydrophobic residues
than eNOS. Additionally, there is a WRKRRK portion on eNOS this is absent from nNOS.
We have proposed that this motif is a MAPK binding site (24). Therefore, eNOS may be
more heavily regulated by MAPKs via the AIL. However, in order to make strong
conclusions, a structural model of the AIL is necessary. While parts of eNOS and other
NOSs have resolved structural information, the AIL has not been elucidated for both
enzymes, therefore it is difficult to attribute differences in activity solely on differences in
the primary structure.
The AIL has not been fully elucidated structurally. However, due to the partial
homology in primary sequence and high conservation of structural elements between NOS
enzyme structures we were able to create a threaded model using the structure of human
iNOS bound to calmodulin (PDB 3HR4). Specifically, we used the flavodoxin-like domain
as our template for the model because of the high structural conservation between eNOS
and iNOS which includes multiple alpha helices and beta strands that can act as anchor
points. Three sites found on the AIL have been published to directly influence eNOS
activity in the literature ser615, ser633, and tyr657 (none shown in figure 2). Of these sites,
tyr657 has been structurally resolved in multiple reported NOS structures and is found in
the FMN binding site which explains how phosphorylation could sterically hinder FMN
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binding and cause the reported inhibitory effect (40). The other serine sites known to
influence eNOS activity are more likely to be near the FMN bound to eNOS acting to
enhance electron transport. However, since these sites are not fully elucidated structurally,
exact positions in the structure of eNOS are not entirely known. One site that is also found
in the AIL is ser600, this site is near the base of a helix that is completely resolved and
involved in the FMN binding domain of the flavodoxin-like domain of eNOS (shown in
purple in figure 2). This makes it more likely that ser600 is more not influencing activity
due to the distance from the FMN. However, phosphorylation at ser600 could influence
eNOS binding partners resulting in an indirect activity changes or changes in subcellular
localization.
In testing our phosphospecific ser600 antibody, we observed a significantly elevated
level of staining in rounded cells that were partially detached from the slide. At first, we
thought this staining was identifying cells undergoing apoptosis, but after closer inspection,
it appeared that the DNA was not fragmenting but rather condensing like at the start of
mitosis. This was verified using flow cytometry and looking at DNA density where we
observe a small population of P-ser600 elevated cells that corresponds to the percentage of
cells that could be in mitosis in an asynchronous population. The DNA staining matched
with N=4 DNA suggesting late cell cycle cells are P-ser600 elevated (figure 3). Additionally,
we were able to increase the population of P-ser600 using a CDK 1 inhibitor – RO-3306 –
to synchronize cells at the G2/M checkpoint (figure 4). This inhibitor is reversible and
therefore should minimally interact with other kinases, but nonetheless it has been reported
to interact with PKC gamma and serum/glucocorticoid-regulated kinase (SGK) with a Ki
(nM) of 318 and 497 respectively. Other kinases that have been shown to phosphorylate

38

eNOS such as, ERK, PKA, and AKT had an approximately 2000 nM Ki or greater (41).
Ultimately, we believe that the inhibitor itself is not directly impacting levels P-ser600 and
is acting as a cell synchronization agent in our conditions. Therefore, by using cell
synchronization and immunofluorescence costaining we observed that P-ser600 is elevated
during mitosis. We further verified this direct link between P-ser600 and mitosis by
detecting histone H3 ser28 phosphorylation which is a mitotic indicator (42). Additionally,
DNA density staining also supports our interpretation. Ultimately, our data supports the
notation that P-ser600 is enhanced during mitosis.
In order to ensure that changes in P-ser600 are not from changing eNOS levels, we
employed both immunofluorescence and flow cytometry. This showed that asynchronous
cells maintain a similar amount of eNOS (figure 5) throughout the cell cycle. When
comparing our data with the literature, we found that eNOS does not significantly change
throughout the cell cycle (43). Therefore, we believe that P-ser600 is not elevated due rising
eNOS levels. However, because our study relies on an antibody to P-ser600 with limited
reported data, we wanted to verify specificity of the antibody. We did this by using a
proximity ligation assay which produces signal only if two antibodies are within 40 nm.
This highly specific assay was employed with a mouse monoclonal antibody to eNOS and
our rabbit anti-P-ser600 antibody. This produced a similar signal to what is observed with
immunostaining of P-ser600, therefore we conclude that our antibody is specific to eNOS
(figure 6). Additionally, we immunoprecipitated with the P-ser600 antibody, collected the
main band around 150 kD, and submitted for mass spectrometry. After a trypsin digestion,
we observed fragments of eNOS protein in our sample (supplemental figure 4). We have
also previously reported that the antibody signal is ablated when treating lysates with
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lambda phosphatase and antibody signal is elevated when eNOS is incubated with ERK
(24). Taken together, this suggests that our antibody is specific to eNOS that is
phosphorylated at ser600.
Our study also found significant elevation in P-ser600 through western blotting by
collecting cell lysates different time points following release of the G2/M block by RO3306. Interestingly, eNOS that was phosphorylated at ser600 was shifted by 10 kD in our
conditions (figure 7). We hypothesize that this shift is the result of some posttranslational
modification that is approximately 10 kD. We also observe a slight, but nonetheless
significant elevation in P-ser1177 (figure 8). Gentile et al. has observed that P-ser1177 is
elevated in mouse embryonic endothelial cells when stimulated with VEGF as part of
angiogenesis in embryonic development (32). Similarly, our data supports that dividing
microvascular endothelial cells have an increase in P-ser1177. This is likely also associated
with angiogenesis mechanisms for formation of new capillaries. However, when
comparing our data with quercetin induced mitotic arrest of bovine aortic endothelial cells,
we do not observe the same modulation in eNOS phosphorylation sites (44). Jackson et al.
found that P-ser114 and P-ser615 are decreased with increasing amounts of mitotic arrest.
Also, Jackson et al. found that P-ser1177 and P-thr495 were consistent regardless of degree
of mitotic arrest. However, under our conditions, we observed consistent levels of P-ser114
phosphorylation, decreasing P-thr495, and increasing P-ser1177. This raises the possibility
that there may be significantly different mechanisms governing the regulation of eNOS
phosphorylation between microvasculature and macrovasculature during cellular division.
We previously reported that ERK can phosphorylate eNOS at ser600 in vitro (24).
Here we show that in situ phosphorylation of ser600 is likely not caused by a MAPK. We
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found that elevation of P-ser600 does not correspond to elevations in MAPK activation
phosphorylation (figure 9). We found that JNK is unable to phosphorylate at ser600 in vitro
and is highly unlikely to phosphorylate in situ (supplemental figure 2). Additionally, we
found that p38 can phosphorylate at ser600 but the phosphorylation of p38 in our time course
does not correspond to changes in P-ser600. ERK was thought to be the physiological
kinases responsible for P-ser600, but the EGF in the media stimulated cells for greater than
2 hours, which does not correspond to the elevation in P-ser600. Together, this rules out
JNK and p38 as the physiological kinase responsible for the phosphorylation in our
conditions. Therefore, we suggest that an EGF independent mechanism of ERK activation
may still be responsible for the elevated P-ser600, but further work is necessary before
strong conclusions can be made. Additionally, we did in vitro kinase activity assays with
eNOS and CDK 1/cyclin B, CDK 2/cyclin E, and CDK 5/p25. We found that CDK 2 and
CDK 5 are both able to phosphorylate at ser600 (supplementary figure 3). Together this tells
us that a CDK could be responsible for the phosphorylation event, but ultimately further
research is necessary to elucidate the kinase responsible for P-ser600.
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CHAPTER 5 – CONCLUSIONS AND FUTURE DIRECTIONS
All together our study has found that ser600 phosphorylation is modulated during
late cell cycle and at the start of mitosis. Additionally, this phosphorylation event is not
attributed to an increase in overall eNOS protein levels. We were able to verify this through
multiple experimental methods ranging from immunofluorescence, flow cytometry and
western blotting. Additionally, we have verified that our P-ser600 antibody is specific to
eNOS that is phosphorylated at ser600 which helps provide additional data to the limited
data available on this antibody. We have attempted to also distinguish which kinases are
responsible for the P-ser600. This resulted in ruling out p38 and JNK for the P-ser600 at the
start of mitosis and found that ERK could be responsible in what would be hypothesized
to be an EGFR independent mechanism, but ultimately further work is necessary to make
stronger conclusions about ERK involvement in ser600 phosphorylation. Additionally, we
found that eNOS is shifted by 10 kD on gels when it is phosphorylated at ser600 which
suggests that another posttranslational modification on eNOS is occurring, one which
causes this 10 kD shift. Even more interestingly, we found that eNOS phosphorylated at
ser600 is found in a unique distribution pattern within cells, but this also needs additionally
research before a stronger conclusion can be made. Taken together, we have presented data
that shows that ser600 is phosphorylated in tissue culture and its modulation in a cell cycle
dependent manner. This work should be replicated using animal models in order to fully
understand the significance of ser600 in the context of the cardiovascular system.
One possible explanation for the role of ser600 phosphorylation physiologically
could be through migration. Our lab had found that CDK 5 is capable of phosphorylating
at ser600. Recently, Lampropoulou et al. found that CDK 5 is involved in endothelial cell
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migration as part of pleiotrophin agonized mechanism. Pleiotrophin is a hypothesized
angiogenic growth factor that is binds with strong affinity to heparin receptors (45).
Together this suggests that a potential physiological roll for eNOS ser600 phosphorylation
could be participation in migration. While ser600 phosphorylation directly does not seem to
influence NO output, when coupled with phosphorylation by an activating kinase, protein
kinase A (PKA), eNOS output is significantly greater than with PKA incubation alone (data
not shown). Additionally, it appears that ser600 phosphorylation in immunofluorescence
shows a unique staining pattern like what is observed when staining with intermediate
filaments suggesting a cytoskeletal specific distribution. The cause of the distribution is
unknown, but we believe that the phosphorylation at ser600 in conjunction with the
additional modification resulting in the observed 10 kD shift on SDS-PAGE could together
result in the unique staining. The increased NO output by eNOS could be the mechanism
used to break down these cytoskeletal elements as part of the pleiotrophin induced CDK 5
mediated endothelial cell migration observed by Lampropoulou (46). One way to test this
would be by using the method described by Ni et al. to immortalize microvascular
endothelial cells from mice. So long as the original eNOS promoter is not changed as part
of the knockout, theoretically, we could introduce a plasmid with that promoter and the
sequence of eNOS with mutations at residues of eNOS we are interested in without the
worry of dealing with the wild type population of eNOS that would be present in simple
transfection experiments with other endothelial cells. It would be interesting to investigate
the role of ser600 on endothelial cell migration using this model system. Additionally, if the
other posttranslational modification we believe is associated with ser600 phosphorylation is
found to be a mono ubiquitin-like modification (approximately 8 kD and includes protein
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like ubiquitin, small ubiquitin-like modifier (SUMO) proteins, or NEDD8), then we could
theoretically mutate the lysine residue to a arginine residue which would be unable to be
modified. This could result in different physiological changes, but we believe the most
likely observation from this set of experiments would be a change in the subcellular
distribution of ser600 phosphorylated eNOS from localization at intermediate filaments to a
cytoplasmic distribution. Additionally, the physiological role of NO in migration could be
perturbed and the rate of migration for cells without the lysine modification could be much
slower as cytoskeletal intermediate filaments may not be broken down as efficiently as the
wild type eNOS. This is one possible explanation for the role of ser600 phosphorylation,
ultimately, a significant amount of work is necessary before stronger conclusions can be
made.
One interesting route of investigation would be to look at differences in ser600
phosphorylation between male-derived compared to female-derived endothelial cells.
Recently, Cattaneo et al. identified that differences in eNOS expression and function
between male-derived and female-derived endothelial cells (42). This group found that
eNOS expression is twice as high in female endothelial cells compared to male endothelial
cells. Additionally, they found that the mechanisms surrounding endothelial functions like
migration was sex specific. For example, they observed that male endothelial cells use an
eNOS independent and cellular proliferation-based mechanism for wound recovery
whereas female endothelial cells use an eNOS dependent and cellular proliferation
independent mechanism. To elaborate, female endothelial cells rely on eNOS to assist in
recovering from wounding and do not simply just divide to fill the wounded area like male
endothelial cells. As part of this mechanism, female endothelial cells get larger than male
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endothelial cells. With the differences in wound recovery in mind, due to the mitotic nature
of ser600 phosphorylation, we believe that male endothelial cells would express elevated
levels of P-ser600 as part of wound recovery and this would not be observed in female
endothelial cells due to the proliferation-independent mechanism governing wound
recovery. This could be the result of differences in gene expression where the network of
genes guiding wound healing are sex specific. However, if P-ser600 is also associated with
a role in breaking down the cellular cytoskeleton, then elevation may also be observed in
female endothelial cells as intermediate filaments are broken down with enhanced
production of NO. Ultimately, over 6,500 protein-coding genes have been found to have
differential expression in adults based on sex (47). This opens the possibility of sex-specific
regulatory elements which could result in totally different regulation mechanisms between
males and females. Ultimately, further research is necessary in order to determine the
influence that sex-specific gene networks have on NOS regulation.
Another route of investigation could be on the regulatory differences between the
microvasculature and macrovasculature. It is well established that the endothelial
phenotype differs slightly based on the vascular bed the endothelial cells are associated
with (48). Despite many physiologically similar functions, endothelial cells are different
segmentally. For example, phenotypically, arterial endothelial cells are different than
capillary endothelial cells which are different than venous endothelial cells. There are two
major classes of endothelium, microvascular and macrovascular. There is ambiguity in the
literature with regards to endothelial functional differences between these two types of
endothelium where some researchers report finding an association between micro- and
macrovasculature and others do not (49-51). This suggests that the underlying mechanism
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may be organ specific and varies by disease. Additionally, it is important to note that the
single layer of endothelium surrounds other organs besides the interior of blood vessels
and is inherently difficult to isolate and study. However, this leaves open the possibility
that endothelium associated with different organs may be regulated differentially. It would
be worth studying the regulatory differences that result in the ambiguity in the literature
regarding the functional association between microvasculature and macrovasculature.
Specifically, it would be interesting in the context of phosphorylation regulation during
mitotic events associated with wound recovery and angiogenesis. As well as, the role of
eNOS ser600 phosphorylation in these conditions. Ultimately, due to limited amount of data
available in the literature with regards to ser600, significantly more research is necessary
before any conclusions can be made with confidence.
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SUPPLEMENTARY INFORMATION
Supplementary Figure 1

Phosphorylation of eNOS at ser600 and ser114 does not significantly alter NO production in vitro.
Phosphorylation of eNOS with a kinase that phosphorylates at activating serine sites results in significant
enhancement of NO production (A). Phosphorylation at ser 600 by ERK and phosphorylation at ser114 and
ser600 by p38 does not significantly alter NO production (B and C respectively). Data from Xzaviar Solone.

Supplementary Figure 2

MAPKs differentially phosphorylate eNOS ser-pro sites. ERK can phosphorylate eNOS at ser600 but
not at ser114. JNK can phosphorylate at ser114 but not at ser600. P38 can phosphorylate at both ser600 and
ser114. Data from Xzaviar Solone.
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Supplementary Figure 3

In vitro kinase assay with CDK 1/cyclin B, CDK 2/cyclin E, and CDK 5/p25. 2.2uM eNOS was
incubated with CDK-1 for 50 minutes and CDK-2 and CDK-5 for 30 minutes. We observe that CDK 1
does not significantly phosphorylate eNOS at ser600 when compared to either CDK 2 or CDK 5. It should
be noted that CDK 1 is significantly less active than CDK 2 and CDK 5. Data from Xzaviar Solone.
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Supplementary Figure 4

Mass spectrometry of eNOS after immunoprecipitation with anti-P-ser600 antibody
Protein Sequence
eNOS Position
[R].CLGSLVFPR.[K]
99-107
[R].DFINQYYSSIK.[R]
129-139
[R].SAITVFPQR.[SC]
226-234
[R].IWNSQLVR.[Y]
243-250
[R].FNSISCSDPLVSSWR.[R]
613-627
[K].ESSNTDSAGALGTLR.[F]
632-646
[R].LLQLGQGDELCGQEEAFR.[G]
679-696
[R].LSAQAEGLQLLPGLIHVHR.[R]
737-755
[K].GSPGGPPPGWVR.[D]
835-846
[R].LLSTLAEEPR.[E]
876-885
[R].EQQELEALSQDPR.[R]
886-898
[R].LPPDPSLPCILVGPGTGIAPFR.[G]
1001-1022
[K].TYVQDILR.[T]
1086-1093
[R].ILATEGDMELDEAGDVIGVLR.[D]
1130-1150
[R].YHEDIFGLTLR.[T]
1155-1165
Mass spectrometry of eNOS band after immunoprecipitation with our anti-P-ser600 antibody.
Immunoprecipitation with our anti-P-ser600 antibody on HMEC lysates collected 45 minutes after RO3306 washout (blue) and untreated (white). The P-ser600 band (red) has reactivity with BD eNOS band
(green) in the first elution. (TOP of figure) It should be noted ser602 (in the blot above) is bovine
numbering whereas ser600 is human numbering. Detected eNOS fragments from mass spectrometry
(BOTTOM of figure). Data from Morgan Watson.
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Table 3: NOS sequences used in phylogenetic study of phosphorylation sites
Uniprot identifier
G1M5X2_AILME
A0A3Q0SYZ0_AMPCI

H9GDL4_ANOCA

A0A2K5EWR1_AOTNA
A0A3P8QYB8_ASTCA

A0A383YRM3_BALAS

A0A3Q1LSD1_BOVIN
F6VF63_CALJA
A0A3Q7NHI9_CALUR
S9WKR6_CAMFR

F1PV05_CANLF
A0A452EGA9_CAPHI
H0V302_CAVPO
A0A2K5S0Y5_CEBCA
A0A2K5NCZ8_CERAT

A0A0D9R373_CHLSB

A0A2K5IDK8_COLAP
A0A3L7HAM2_CRIGR

A0A2Y9NEZ8_DELLE

Organism
Ailuropoda melanoleuca
(Giant panda)
Amphilophus citrinellus
(Midas cichlid) (Cichlasoma
citrinellum)
Anolis carolinensis (Green
anole) (American
chameleon)
Aotus nancymaae (Ma's
night monkey)
Astatotilapia calliptera
(Eastern happy) (Chromis
callipterus)
Balaenoptera acutorostrata
scammoni (North Pacific
minke whale) (Balaenoptera
davidsoni)
Bos taurus (Bovine)
Callithrix jacchus (Whitetufted-ear marmoset)
Callorhinus ursinus
(Northern fur seal)
Camelus ferus (Wild bactrian
camel) (Camelus bactrianus
ferus)
Canis lupus familiaris (Dog)
(Canis familiaris)
Capra hircus (Goat)
Cavia porcellus (Guinea pig)
Cebus capucinus imitator
Cercocebus atys (Sooty
mangabey) (Cercocebus
torquatus atys)
Chlorocebus sabaeus (Green
monkey) (Cercopithecus
sabaeus)
Colobus angolensis palliatus
(Peters' Angolan colobus)
Cricetulus griseus (Chinese
hamster) (Cricetulus
barabensis griseus)
Delphinapterus leucas
(Beluga whale)

Length
1208
1428

1126

1203
1428

1205

1205
1203
1203
936

1211
1193
1206
1203
1205

867

1205
1194

1205
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A0A1S3G337_DIPOR
A0A2Y9K7I3_ENHLU
F6REP3_HORSE
A0A1S3AL81_ERIEU

M3WID9_FELCA
U3JXC0_FICAL

A0A091D6A0_FUKDA

V9ITD3_CHICK
G3RKZ4_GORGO
A0A3P4RQQ4_GULGU
A0A3Q2VEN8_HAPBU

A0A0N8ETM2_HETGA
A0A3M0JYH6_HIRRU
NOS3_HUMAN
A0A287D6H1_ICTTR

W5MAD9_LEPOC
A0A340YEP3_LIPVE
G3SZA3_LOXAF
A0A2K5TWM8_MACFA

A0A1D5QGM1_MACM
U
A0A2K6B252_MACNE

Dipodomys ordii (Ord's
kangaroo rat)
Enhydra lutris kenyoni
Equus caballus (Horse)
Erinaceus europaeus
(Western European
hedgehog)
Felis catus (Cat) (Felis
silvestris catus)
Ficedula albicollis (Collared
flycatcher) (Muscicapa
albicollis)
Fukomys damarensis
(Damaraland mole rat)
(Cryptomys damarensis)
Gallus gallus (Chicken)
Gorilla gorilla gorilla
(Western lowland gorilla)
Gulo gulo (Wolverine)
(Gluton)
Haplochromis burtoni
(Burton's mouthbrooder)
(Chromis burtoni)
Heterocephalus glaber
(Naked mole rat)
Hirundo rustica
Homo sapiens (Human)
Ictidomys tridecemlineatus
(Thirteen-lined ground
squirrel) (Spermophilus
tridecemlineatus)
Lepisosteus oculatus
(Spotted gar)
Lipotes vexillifer (Yangtze
river dolphin)
Loxodonta africana (African
elephant)
Macaca fascicularis (Crabeating macaque)
(Cynomolgus monkey)
Macaca mulatta (Rhesus
macaque)
Macaca nemestrina (Pigtailed macaque)

1201
1202
1204
1012

1202
1435

1206

1146
997
997
1428

1206
1160
1203
1202

1123
1205
1199
1205

1205
1205
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A0A2K5YFH5_MANLE
A0A3P9CX80_9CICH
A0A1U7RHA5_MESAU
F6S3S1_MONDO
NOS3_MOUSE
M3Y867_MUSPF

S7NFW7_MYOBR
G1PQK0_MYOLU
A0A2Y9HAI4_NEOSC

A0A341C675_9CETA

G1QV96_NOMLE

A0A0U1UVC9_OCHCU
A0A2U3WJA4_ODORO
I3JWS0_ORENI
D7RVB4_RABIT
H0X6T1_OTOGA

Q4U3W6_SHEEP
H2QVM2_PANTR
A0A096NXX3_PAPAN
A0A402FCB4_9SAUR
A0A2Y9FMB5_PHYMC

Mandrillus leucophaeus
(Drill) (Papio leucophaeus)
Maylandia zebra (zebra
mbuna)
Mesocricetus auratus
(Golden hamster)
Monodelphis domestica
(Gray short-tailed opossum)
Mus musculus (Mouse)
Mustela putorius furo
(European domestic ferret)
(Mustela furo)
Myotis brandtii (Brandt's bat)
Myotis lucifugus (Little
brown bat)
Neomonachus schauinslandi
(Hawaiian monk seal)
(Monachus schauinslandi)
Neophocaena asiaeorientalis
asiaeorientalis (Yangtze
finless porpoise)
Nomascus leucogenys
(Northern white-cheeked
gibbon) (Hylobates
leucogenys)
Ochotona curzoniae (Blacklipped pika)
Odobenus rosmarus
divergens (Pacific walrus)
Oreochromis niloticus (Nile
tilapia) (Tilapia nilotica)
Oryctolagus cuniculus
(Rabbit)
Otolemur garnettii (Smalleared galago) (Garnett's
greater bushbaby)
Ovis aries (Sheep)
Pan troglodytes
(Chimpanzee)
Papio anubis (Olive baboon)
Paroedura picta
Physeter macrocephalus
(Sperm whale) (Physeter
catodon)

1155
1428
1202
1193
1202
1211

1213
1203
1202

1205

1128

1211
1207
1428
1209
1434

1205
1203
1205
1074
1205
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A0A2J8RKC7_PONAB

A0A2K6F776_PROCO

L5K1F9_PTEAL
F1LQC7_RAT
A0A2K6MEG7_RHIBE

A0A2K6PX93_RHIRO

A0A2K6SCK8_SAIBB

A0A1W4YWX6_SCLFO

Q7YSG7_PIG
A0A1U7UF18_TARSY
A0A2Y9DDV9_TRIMA
L9KPE7_TUPCH
A0A452SJK1_URSAM

A0A3Q7TG73_URSAR
A0A384BW74_URSMA
A0A3Q7RVW8_VULVU
Q800E5_XENLA
F6VMJ0_XENTR

Pongo abelii (Sumatran
orangutan) (Pongo pygmaeus
abelii)
Propithecus coquereli
(Coquerel's sifaka)
(Propithecus verreauxi
coquereli)
Pteropus alecto (Black flying
fox)
Rattus norvegicus (Rat)
Rhinopithecus bieti (Black
snub-nosed monkey)
(Pygathrix bieti)
Rhinopithecus roxellana
(Golden snub-nosed monkey)
(Pygathrix roxellana)
Saimiri boliviensis
boliviensis (Bolivian squirrel
monkey)
Scleropages formosus (Asian
bonytongue) (Osteoglossum
formosum)
Sus scrofa (Pig)
Tarsius syrichta (Philippine
tarsier)
Trichechus manatus
latirostris (Florida manatee)
Tupaia chinensis (Chinese
tree shrew)
Ursus americanus (American
black bear) (Euarctos
americanus)
Ursus arctos horribilis
Ursus maritimus (Polar bear)
(Thalarctos maritimus)
Vulpes vulpes (Red fox)
Xenopus laevis (African
clawed frog)
Xenopus tropicalis (Western
clawed frog) (Silurana
tropicalis)

1203

994

1200
1202
1205

1205

1203

1420

1205
1200
1208
1213
1202

1201
1198
1204
1419
1144
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APPENDIX
Table of Buffers and Recipes
Protocol
Immunofluorescence

Buffer
Blocking buffer/washing
buffer

Recipe/Composition
5% horse serum, 0.3%
Triton X-100, and 0.01%
sodium azide in PBS.

Flow Cytometry

Wash buffer
Blocking buffer

0.5% BSA in PBS
3% BSA, 0.1% Triton X100, and 100 μg/mL
RNase A in PBS.

Western Blotting

Wash buffer
Blocking buffer

In house TBST
Prometheus OneBlock
Western-FL Blocking
Buffer
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Table of Primary and Secondary Antibodies and Antibody Dilutions
Protocol

Name

Type

Dilution

IF

Rabbit eNOS p602 or p600
Rat Histone H3 s28 phospho
Rabbit eNOS
Mouse eNOS
Mouse Vimentin
Donkey anti-Mouse 555
Goat anti-Rabbit 488
Donkey anti-Rat 568
Rabbit eNOS p602
Mouse eNOS-647

Primary
Primary
Primary
Primary
Primary
Secondary
Secondary
Secondary
Primary
Primary

Donkey anti-rabbit 647
Mouse eNOS
Rabbit ERK
Mouse P-ERK
Rabbit p38
Mouse P-p38
Rabbit P-JNK
Goat GAPDH
Rabbit eNOS P-s1177

Secondary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary

1:200
1:100
1:100
1:100
1:100
1:500
1:250
1:750
1:200
20 μL/
100k
cells
1:2000
1:1000
1:1000
1:2000
1:1000
1:2000
1:1000
1:1000
1:1000

Rabbit eNOS P-s615
Rabbit eNOS P-t495
Mouse eNOS P-s632
Rabbit eNOS P-s114

Primary
Primary
Primary
Primary

1:500
1:1000
1:1000
1:1000

Flow
Cytometry

Western
Blotting

Manufacturer –
catalog #
Abcam – ab10543
Santa Cruz – SC654
BD - 610297
Santa Cruz – SC-6260
Invitrogen - A32773
Invitrogen - A-11034
Abcam - ab175475
BD - 560102

Abcam - ab150075
BD - 610297
CST – CST 9102
CST – CST 9106
CST – CST 9212
CST – CST 9216
CST – CST 9251
Abcam – ab9483
R&D systems MAB9028
Abcam - ab138458
CST – CST 9574
Abcam – ab76199
Millipore – 07-357
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